By Paul Ziobro
Trevi Therapeutics said a study regarding the human-abuse potential of an oral drug to treat chronic cough in certain patients yielded positive results.
The company on Tuesday said that a study of oral nalbuphine showed clinical doses of the drug demonstrated a statistically significant lower "drug liking" compared with intravenous butorphanol. Meanwhile, a supratherpeutic dose was numerically lower than the intravenous butorphanol, but the results were not statistically significant.
James Cassella, Trevi's chief development officer, said the company was pleased with the results.
Trevi is developing the Haduvio, an oral naluphine extended release drug that treats chronic cough in patients with idiopathic pulmonary fibrosis and refractory chronic cough. Haduvio acts on the cough reflex arc both centrally and peripherally as a kappa agonist and a mu antagonist, which are opioid receptors that play a key role in controlling cough.
Nalbuphine is currently unscheduled in the U.S. and has been for several decades, according to Jack Henningfield, vice president of research, health policy and abuse liability at Pinney Associates. Part of the study is to demonstrate that the drug doesn't pose the same safety risks as do other opioids that are often prescribed for chronic cough.
Write to Paul Ziobro at paul.ziobro@wsj.com
(END) Dow Jones Newswires
December 03, 2024 17:30 ET (22:30 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.